AAP
CUE icon

Arax Advisory Partners’s Cue Biopharma CUE Stock Holding History

Arax Advisory Partners’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7
Closed -$163 – 2500
2024
Q3 		$163 Hold
7
– – ﹤0.01% 2528
2024
Q2 		$267 Buy
+7
New +$346 ﹤0.01% 2416

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Arax Advisory Partners's CUE Position: Q4 2024 in Review

Arax Advisory Partners sold out of Cue Biopharma (CUE) in Q4 2024, closing a stake of 7 shares — an estimated $163 sold.

Arax Advisory Partners first reported a position in CUE in Q2 2024 and held it in 2 quarters. The position peaked at $267 in Q2 2024. 54 funds tracked by Wall St. Rank hold CUE as of Q4 2024.

  • Arax Advisory Partners reported no remaining Cue Biopharma position as of Q4 2024 after selling out during the quarter.
  • Arax Advisory Partners sold 7 Cue Biopharma shares in Q4 2024, an estimated $163.
  • Arax Advisory Partners first reported a position in Cue Biopharma in Q2 2024 and held it in 2 quarters.
  • Arax Advisory Partners's Cue Biopharma position peaked at $267 in Q2 2024.
  • 54 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.